SOSTOS
A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels (SOSTOS)
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase IV
- Conditions Being Studied: Brain and Nervous System
Study Purpose
MS is a long-term illness where the body’s immune system attacks and damages the protective covering (called myelin) around the nerves in the central nervous system. People with relapsing MS (relapsing-remitting MS or secondary progressive MS with relapses) will have repeated attacks, or “relapses.” The purpose of the study is to find out if patients who have not had a relapse in the past year would benefit from switching to ofatumumab compared to continuing their current MS treatment. This study will also look at serum neurofilament light (NfL). NfL is a biomarker that may be an indicator of damage in a variety of neurological disorders.
Who Can Participate
Age: 18-45 years old
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Minoff Health Center at Chagrin Highlands
3909 Orange Pl
Orange Village OH, 44122
UH Suburban Health Center
1611 S Green Rd
South Euclid OH, 44121
- UH IRB: SITE00001945 / STUDY20230207
- StudyID: 2022-0964
- ClinicalTrials.gov: NCT05090371
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422